Condition: Exudative Age-related Macular Degeneration · Sponsor: Nantes University Hospital
The objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (AMD). This involves questioning its beneficence/non-maleficence ratio given the limited experience with this innovative technology and its irreversible effects, requiring a surgical procedure for administration. Additionally, the study explores patient autonomy in decision-making concerning complex therapeutic approaches and how patients should be supported to best uphold this autonomy.
This description comes directly from the study's public registry record.
Helene Masse, M.D · +33 2 53 48 28 57 · helene.masse@chu-nantes.fr
Alexandra Poinas, PhD · +33 2 53 48 28 57 · alexandra.poinas@chu-nantes.fr
Always discuss trial participation with your own doctor first.
| CHU Nantes - Ophthalmology Department | Nantes, Nantes, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07004361